Trevi Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating income | -$49.3 | -$51.5 | -$33.9 | -$29.9 | -$32.5 |
| Net income | -$42.8 | -$47.9 | -$29.1 | -$29.2 | -$33.9 |
| Cash Flow Statement | |||||
| Free cash flow | -$42.1 | -$38.3 | -$31.8 | -$28.3 | — |
Shares outstanding 142.5M · Free float 38.4%
Annual filing data through FY ended December 31, 2025; float as of September 30, 2026.